<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Rituximab (RTX) is a chimeric anti-CD20 antibody, approved for <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (RA) patients who failed anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> <z:mp ids='MP_0001651'>Necrosis</z:mp> Factor therapy </plain></SENT>
<SENT sid="1" pm="."><plain>It has been used occasionally for life-threatening <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> (AID) </plain></SENT>
<SENT sid="2" pm="."><plain>We report our center experience in the use of RTX in life-threatening complications or refractory AID </plain></SENT>
<SENT sid="3" pm="."><plain>Clinical charts of patients treated with RTX at our center were reviewed, cases treated for life-threatening complications or refractory AID were analyzed </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> damage to vital organs such as lung, heart, kidney, <z:mp ids='MP_0008912'>nervous</z:mp> system with severe functional impairment were defined as life-threatening complications; treatment failure with high-dose <z:chebi fb="0" ids="50858">corticosteroids</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, IVIG, plasmapheresis was defined as refractory <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>During the years 2003-2009, 117 patients were treated with RTX, most of them for RA </plain></SENT>
<SENT sid="6" pm="."><plain>Nine patients (6 females, mean age 51.5 years, mean disease duration 6.3 years) answered the criteria </plain></SENT>
<SENT sid="7" pm="."><plain>The indications were as follows: <z:mp ids='MP_0001182'>pulmonary hemorrhage</z:mp> (1 patient with cryoglobulinemic <z:hpo ids='HP_0002633'>vasculitis</z:hpo>, 1 with systemic <z:mp ids='MP_0000612'>sclerosis</z:mp>, 1 with <z:chebi fb="0" ids="34507">ANCA</z:chebi>-associated <z:hpo ids='HP_0002633'>vasculitis</z:hpo>), catastrophic anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> syndrome (2 SLE patients), non-<z:hpo ids='HP_0006689'>bacterial endocarditis</z:hpo> and <z:hpo ids='HP_0002092'>pulmonary hypertension</z:hpo> (1 patient with <z:e sem="disease" ids="C0026272" disease_type="Disease or Syndrome" abbrv="MCTD">mixed connective tissue disease</z:e>), <z:hpo ids='HP_0002633'>vasculitis</z:hpo> and feet <z:mp ids='MP_0001651'>necrosis</z:mp> (1 patient with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo>), severe <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> demyelinative <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> and <z:hpo ids='HP_0001919'>acute renal failure</z:hpo> (1patient), and severe <z:e sem="disease" ids="C0994344" disease_type="Disease or Syndrome" abbrv="">rheumatoid lung disease</z:e> with recurrent <z:mpath ids='MPATH_609'>empyema</z:mpath> and <z:hpo ids='HP_0002107'>pneumothorax</z:hpo> (1patient) </plain></SENT>
<SENT sid="8" pm="."><plain>B cell <z:mpath ids='MPATH_63'>depletion</z:mpath> was achieved in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="9" pm="."><plain>The median time since starting of complications to RTX administration was 3 weeks (range 2-15 weeks) </plain></SENT>
<SENT sid="10" pm="."><plain>Complete remission (suppression of the hazardous situation and return to previous stable state) was seen in 7 out of 9 patients </plain></SENT>
<SENT sid="11" pm="."><plain>Partial remission (significant improvement) was achieved in the remained </plain></SENT>
<SENT sid="12" pm="."><plain>The median time to response was 3 weeks (range 1-8 weeks), mean follow-up 47.2 months (range 6-60 months) </plain></SENT>
<SENT sid="13" pm="."><plain>A rapid tapering off of steroids was achieved in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="14" pm="."><plain>Two patients relapsed and were successfully retreated with RTX: the patient with severe RA lung relapsed after 3 years, one of the patients with <z:chebi fb="0" ids="34507">ANCA</z:chebi>-associated <z:mp ids='MP_0010909'>pulmonary alveolar hemorrhage</z:mp> relapsed after 10 months </plain></SENT>
<SENT sid="15" pm="."><plain>There were no side effects during RTX infusion </plain></SENT>
<SENT sid="16" pm="."><plain>Two episodes of serious <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> were registered: fatal <z:mp ids='MP_0001795'>Gram-negative</z:mp> <z:hpo ids='HP_0100806'>sepsis</z:hpo> 6 months after RTX treatment, and septic <z:e sem="disease" ids="C0012624" disease_type="Disease or Syndrome" abbrv="">discitis</z:e> 4 months after receiving RTX </plain></SENT>
<SENT sid="17" pm="."><plain>RTX serves as a safe, efficient, and prompt rescue therapy in certain life-threatening conditions and resistant to aggressive immunosuppression AID </plain></SENT>
<SENT sid="18" pm="."><plain>RTX when administrated at an earlier stage, prevented irreversible vital organ damage, and allowed rapid steroid tapering off in already severe immunodepressed patients </plain></SENT>
</text></document>